<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>研发客 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-05T07:18:24+08:00</updated>
  <subtitle>《研发客》公众号由上海汐潮信息技术有限公司提供，行业资深中英文独立编辑记者创办。我们观察药物创新生态，报道临床研究与监管科学。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>我眼中的“阿尔法折叠”｜老梁说药</title>
    <updated>2020-12-04T22:48:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/Uo5jLyHx_3wmDvNfRhrk3g</id>
    <link href="https://mp.weixin.qq.com/s/Uo5jLyHx_3wmDvNfRhrk3g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球首个针对HAE的单抗药物达泽优®（拉那利尤单抗注射液）获批进入中国 | 新闻稿</title>
    <updated>2020-12-04T22:48:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/Z9656mubw51oROvhXOS3KA</id>
    <link href="https://mp.weixin.qq.com/s/Z9656mubw51oROvhXOS3KA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>踩下药物警戒生态化建设的油门 | 第一现场</title>
    <updated>2020-12-03T21:58:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/wqEqCupU9Aerl5o2Ar4gHg</id>
    <link href="https://mp.weixin.qq.com/s/wqEqCupU9Aerl5o2Ar4gHg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>德琪医药在多个亚太市场提交XPOVIO®（Selinexor）的新药上市申请 | 新闻稿</title>
    <updated>2020-12-03T21:58:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-03:/s/uiewPKHBDNdttLvlp7CuFg</id>
    <link href="https://mp.weixin.qq.com/s/uiewPKHBDNdttLvlp7CuFg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>MRCT在中国（三）：对照药的国际采购｜ 客论</title>
    <updated>2020-12-02T23:00:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/_OMtYKcskT8cvzWBUrPppQ</id>
    <link href="https://mp.weixin.qq.com/s/_OMtYKcskT8cvzWBUrPppQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新法规下三类和五类化药临床研究和注册策略研讨会 | 会讯</title>
    <updated>2020-12-02T23:00:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/rlkOyP0WNtry3NfPGcjCaw</id>
    <link href="https://mp.weixin.qq.com/s/rlkOyP0WNtry3NfPGcjCaw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>MRCT在中国（二）：本土创新海外临床势如破竹 ｜ 客论</title>
    <updated>2020-12-01T21:51:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/Nf1Usfz3W3vBkc939nMjaA</id>
    <link href="https://mp.weixin.qq.com/s/Nf1Usfz3W3vBkc939nMjaA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Selinexor III期临床研究SEAL数据在2020年结缔组织肿瘤学会年会发布并作口头报告 ｜ 新闻稿</title>
    <updated>2020-12-01T21:51:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/u8a1eKvUmj0N9jIZ5esXEA</id>
    <link href="https://mp.weixin.qq.com/s/u8a1eKvUmj0N9jIZ5esXEA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>聚焦国际首创，泽生科技蝉联“中国医药企业创新100强”第一梯级 | 新闻稿</title>
    <updated>2020-12-01T21:51:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/bwEaRVPAY7qzOm_bZVsOTQ</id>
    <link href="https://mp.weixin.qq.com/s/bwEaRVPAY7qzOm_bZVsOTQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>再鼎医药任命Alan Sandler博士为总裁暨肿瘤领域全球开发负责人 | 新闻稿</title>
    <updated>2020-12-01T21:51:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-01:/s/kLQPU0_POUraGtVzPeU0tw</id>
    <link href="https://mp.weixin.qq.com/s/kLQPU0_POUraGtVzPeU0tw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>​MRCT在中国（一）：外企历经风雨终见彩虹 ｜ 客论</title>
    <updated>2020-11-30T20:55:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/ybjGaS8sLI0DGnxVBbAyZg</id>
    <link href="https://mp.weixin.qq.com/s/ybjGaS8sLI0DGnxVBbAyZg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>​派格生物完成pre-IPO轮融资，全面推进慢病创新药管线开发｜新闻稿</title>
    <updated>2020-11-30T20:55:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/4KINOR6BQvwMnBSYeja1RQ</id>
    <link href="https://mp.weixin.qq.com/s/4KINOR6BQvwMnBSYeja1RQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>凯信远达：专注血液肿瘤，期待扭亏为盈｜公司分析</title>
    <updated>2020-11-30T20:55:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/9GclkNbUMqQSdsz9qRUJag</id>
    <link href="https://mp.weixin.qq.com/s/9GclkNbUMqQSdsz9qRUJag" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>辉瑞：将更多关键性临床试验同步到中国 | DRR专题·外企临床研究策略</title>
    <updated>2020-11-29T21:54:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-29:/s/N0kl75H5aRw-6Gpwv_d4Cg</id>
    <link href="https://mp.weixin.qq.com/s/N0kl75H5aRw-6Gpwv_d4Cg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>专注眼科创新药研发  典晶生物完成五千万美元A轮融资 | 新闻稿</title>
    <updated>2020-11-29T21:54:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-29:/s/bcuCvfEKJSbYusXUlgTnVQ</id>
    <link href="https://mp.weixin.qq.com/s/bcuCvfEKJSbYusXUlgTnVQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>德琪医药梅建明博士荣膺“2020中国经济新闻人物·新经济领军人物” ｜新闻稿</title>
    <updated>2020-11-29T21:54:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-29:/s/xpmVL_TEZjNsLFFn7PFLeA</id>
    <link href="https://mp.weixin.qq.com/s/xpmVL_TEZjNsLFFn7PFLeA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药品专利补偿和专利链接制度何去何从 | 新闻稿</title>
    <updated>2020-11-28T22:00:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-28:/s/vgYGjZ8P2hCXeWZUD3X_wg</id>
    <link href="https://mp.weixin.qq.com/s/vgYGjZ8P2hCXeWZUD3X_wg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>勃林格殷格翰创新大赛：与本土创新携手同行｜第一现场</title>
    <updated>2020-11-26T21:58:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/wunv6izniiNn475qEBCl2Q</id>
    <link href="https://mp.weixin.qq.com/s/wunv6izniiNn475qEBCl2Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第二代选择性核输出抑制剂ATG-016(Eltanexor)治疗骨髓增生异常综合征在中国获I/II期临床试验批准｜新闻稿</title>
    <updated>2020-11-26T21:58:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/LnJZVg-JHPgdVyePpAfwRA</id>
    <link href="https://mp.weixin.qq.com/s/LnJZVg-JHPgdVyePpAfwRA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>阿斯利康新冠疫苗达到预防COVID-19主要疗效终点 | 第一现场</title>
    <updated>2020-11-25T21:26:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/SCsKzxr5vKkITfWepPy-0Q</id>
    <link href="https://mp.weixin.qq.com/s/SCsKzxr5vKkITfWepPy-0Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>